AXIM Biotechnologies, Inc.
AXIM Biotechnologies, Inc., a leading player in the biotechnology sector, is headquartered in the United States. Founded in 2014, the company has made significant strides in the development of innovative cannabinoid-based products, focusing on areas such as pharmaceuticals, diagnostics, and consumer goods. AXIM is renowned for its unique offerings, including proprietary formulations that leverage the therapeutic potential of cannabinoids. The company’s commitment to research and development has positioned it as a pioneer in the industry, with notable achievements in clinical trials and product launches. With a strong market presence, AXIM Biotechnologies continues to drive advancements in cannabinoid science, aiming to improve health outcomes and enhance quality of life for patients worldwide.
DitchCarbon Score
How does AXIM Biotechnologies, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AXIM Biotechnologies, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AXIM Biotechnologies, Inc.'s reported carbon emissions
AXIM Biotechnologies, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As there are no emissions data or reduction initiatives available, AXIM Biotechnologies appears to be in the early stages of addressing climate commitments. The absence of inherited emissions data from a parent company or corporate family indicates that the organisation is operating independently in this regard. In the context of the biotechnology industry, it is increasingly important for companies to develop and implement strategies for carbon reduction and sustainability. As the sector evolves, AXIM Biotechnologies may consider aligning with industry standards and best practices to enhance its environmental performance and meet stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AXIM Biotechnologies, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
